RxDoctor Payments Data

Teresa Rosser

Family · Loganville, GANPI 1326691171

Payments from drug & device makers

$10,623in general payments, 2019–2025

Across 498 payments — averaging $21.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1K
  • Merck$747
  • Pharmacyclics LLC, An Abbvie Company$704
  • Johnson & Johnson$626
  • AbbVie$534
  • Sanofi$422
  • plus $7K from 54 others

What the payments were for

  • Food & beverage$10,09995%
  • Education$5245%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis49$1,006
Merck31$747
Pharmacyclics LLC, An Abbvie Company34$704
Johnson & Johnson26$626
AbbVie24$534
Sanofi17$422
Daiichi Sankyo Inc.20$408
Takeda Pharmaceuticals U.S.A., Inc.16$406
Seagen Inc.19$395
GSK23$392
Incyte Corporation13$384
AstraZeneca(2 entities)21$378
Amgen18$313
Gilead15$294
Exelixis Inc.13$261
Stemline Therapeutics Inc.9$249
Genentech USA, Inc.12$226
Bristol Myers Squibb10$211
Eisai Inc.10$205
Bayer10$204
Pfizer9$181
EMD Serono, Inc.8$144
Karyopharm Therapeutics Inc.6$126
Regeneron Healthcare Solutions, Inc.5$120
Lilly USA, LLC5$109
Sanofi-aventis U.S. LLC1$100
Jazz Pharmaceuticals Inc.3$100
Beigene USA, Inc.4$88
AVEO Pharmaceuticals, Inc.3$70
Astellas Pharma US Inc4$68
Acrotech Biopharma Inc.4$65
Boehringer Ingelheim3$61
Rigel Pharmaceuticals, Inc.3$61
Taiho Oncology, Inc.2$58
ADC Therapeutics America, Inc.3$57
Epizyme, Inc.3$56
Pharmaessentia USA Corporation3$55
Ipsen Biopharmaceuticals, Inc2$53
Tersera Therapeutics LLC2$52
Adaptive Biotechnologies Corporation3$50
Genmab U.S., Inc.3$46
Apellis Pharmaceuticals, Inc.2$46
Deciphera Pharmaceuticals Inc.3$45
Beone Medicines USA, Inc.2$43
Sobi, Inc2$40
Coherus Oncology, Inc.2$40
Servier Pharmaceuticals LLC2$33
E.r. Squibb & Sons, L.L.C.2$31
Array Biopharma Inc2$30
Geron Corporation1$28
Sun Pharmaceutical Industries Inc.1$25
Dendreon Pharmaceuticals LLC1$24
Legend Biotech USA Inc.1$21
Sumitomo Pharma America, Inc.1$21
Organon1$20
Myriad Genetic Laboratories, Inc.1$17
Acceleron Pharma, Inc.1$16
Spectrum Pharmaceuticals Inc.1$16
Kyowa Kirin, Inc.1$15
Blueprint Medicines Corporation1$14

How this compares

$10,623 in reported general payments places this provider in the 95th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$86,711
Medicare patients
43
Services billed
4,365

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide75$1,287,675
PomalystPomalidomide14$316,553
TagrissoOsimertinib Mesylate20$306,787
JakafiRuxolitinib Phosphate20$245,615
VenclextaVenetoclax17$196,236
EliquisApixaban108$79,148
XareltoRivaroxaban15$11,708
Ondansetron Hcl82$1,559
Anastrozole69$1,291
Prochlorperazine Maleate73$788
Dexamethasone46$745
Tamoxifen Citrate29$735
Acyclovir56$569
Letrozole28$562
Ondansetron OdtOndansetron22$560

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$211$1,287,67575 claims
E.r. Squibb & Sons, L.L.C.Pomalyst$31$316,55314 claims
AstraZenecaTagrisso$378$306,78720 claims
Incyte CorporationJakafi$384$245,61520 claims
AbbVieVenclexta$534$196,23617 claims
PfizerEliquis$181$79,148108 claims
Johnson & JohnsonXarelto$626$11,70815 claims
Lilly USA, LLCOlanzapine$109$25618 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,258 family providers in Georgia.

Other family in Loganville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →